Niaosong District

Researchers are evaluating the effects of amniotic suspension allograft ASA injections compared to hyaluronic acid HA and saline injections for treating knee osteoarthritis in adults aged 18 to 80. This condition involves joint cartilage damage and inflammation leading to pain and decreased mobility. The study aims to find the best ASA dose and assess its potential to reduce inflammation and improve quality of life compared to existing injection treatments. Participants will be randomly assigned to receive one of four intra-articular knee injections under ultrasound guidance ASA 40 mg, ASA 20 mg, HA, or saline. ASA injections are prepared by diluting AMNIOGEN tissue in saline, while HA and saline are administered as per standard concentrations. The trial is double-blind, ensuring neither participants nor researchers know the assigned treatment. Injections and follow-up occur over a 12-month period. During the study, participants will undergo assessments including pain scales VAS, NRS, knee injury and osteoarthritis outcome scores KOOS, and quality of life evaluations WHOQOL-BREF. Laboratory tests such as complete blood count, C-reactive protein, erythrocyte sedimentation rate, and cytokine levels will be monitored. Imaging with knee ultrasound and X-ray will assess joint status, alongside cartilage protein measurements. Safety and treatment effects will be observed throughout the 12 months of follow-up.

This research aims to collect real-world data on the characteristics, management, healthcare use, and outcomes of patients living with type 2 diabetes, hypertension, heart failure, and chronic kidney disease. It is an international observational registry that includes patients from many countries to better understand how these conditions are treated in everyday clinical practice. Participants in this registry are observed without receiving experimental treatments. Data are collected both retrospectively and prospectively using a cloud-based electronic case report form accessible to investigators and a scientific committee. The registry includes groups of patients with type 2 diabetes, hypertension, chronic kidney disease, or heart failure, either as their primary condition or as a coexisting condition. Patients provide information about their health status, treatments, and outcomes over time. Researchers collect data on demographics, disease characteristics, laboratory tests, treatments, healthcare visits, hospitalizations, and lifestyle factors. The study measures many outcomes such as blood sugar levels, kidney function, heart function, medication use, and health events over an average of three years. Participation is voluntary and ongoing, with data collection continuing until the study end date in 2030.

Researchers are evaluating the long-term safety of Deucravacitinib compared to Ustekinumab in adults with moderate-to-severe plaque psoriasis. This Phase 3b4 study focuses on cardiovascular events and other health outcomes over an extended period, aiming to understand how these treatments impact patients with psoriasis who have cardiovascular risk factors. The study is led by Bristol-Myers Squibb and involves random assignment of participants to either treatment. Participants receive either Deucravacitinib or Ustekinumab at specified doses on scheduled days. The study is open-label, meaning both participants and researchers know which treatment is being given. This trial runs for up to 5 years, during which patients are monitored for cardiovascular safety and other health events related to their psoriasis treatment. Throughout the study, participants undergo regular assessments to track major cardiovascular events like heart attacks, strokes, and hospitalizations, as well as monitoring for infections, cancer, and treatment side effects. Researchers collect data on liver function and lipid levels up to 60 days after the last dose. The long-term follow-up helps evaluate safety and health outcomes over several years, with study activities continuing until early 2031.

Researchers are evaluating the safety and effectiveness of ADI-PEG 20 in adults with Nonalcoholic Steatohepatitis NASH, a liver condition characterized by fat buildup and inflammation. This phase 2A clinical trial compares ADI-PEG 20 with a placebo to understand its impact on liver fat reduction. The study includes careful monitoring of side effects and laboratory tests to ensure participant safety. Participants receive weekly doses of ADI-PEG 20 or placebo via intramuscular injection at 36 mgm2. The trial is randomized and double-blind, meaning neither participants nor researchers know who receives the active drug or placebo. The treatment period lasts 24 weeks, during which liver fat changes are assessed using MRI-PDFF imaging. An independent committee oversees safety by reviewing adverse events and clinical data. During the study, participants undergo regular health evaluations including vital signs, body weight checks, ECGs, and blood tests. Liver fat levels are measured at the start and at week 24 to assess treatment effects. Safety is monitored continuously through adverse event reporting and laboratory tests. The total participation time spans 24 weeks, with ongoing review of safety and efficacy outcomes throughout.

This research aims to evaluate whether lymphatic surgery improves quality of life better than conservative treatment in patients with chronic breast cancer-related lymphedema BCRL. The study focuses on comparing surgical techniques with the current standard conservative therapy to understand which approach provides better long-term benefits. It is a pragmatic, randomized, international multicenter trial seeking to provide scientific evidence on the effectiveness of surgery over conservative care for this condition. Participants will be randomly assigned to one of two groups. The surgical group may receive lymphovenous anastomosis LVA, vascularized lymph node transfer VLNT, or a combination of both, with some possibly also undergoing liposuction depending on local standards. The conservative group will receive complex physical decongestion therapy CDT, which includes manual lymphatic drainage, compression bandages and garments, physical exercises, and skin care. Both treatments are delivered according to usual care practices, with treatment details and frequency documented. Throughout the study, participants will complete quality of life questionnaires at baseline and 15 months after randomization, with further assessments up to 10 years. Researchers will monitor changes in pain, surgical complications, lymphangitic events, arm volume, frequency of lymphatic drainage, patient burden, and economic impact. The study involves long-term follow-up to evaluate outcomes, safety, and treatment effects, with participation lasting up to 10 years.